Guidelines for Stability Testing of Drugs with Novel Delivery Systems as per US FDA Guidelines
1) Purpose
The purpose of this Standard Operating Procedure (SOP) is to provide guidelines for conducting stability testing for drugs with novel delivery systems in accordance with US FDA requirements. This SOP ensures that stability data supports the quality, safety, and efficacy of these drugs throughout their shelf life.
2) Scope
This SOP applies to all personnel involved in the design, execution, and documentation of stability studies for drugs with novel delivery systems intended for the US market.
3) Responsibilities
Stability Testing Team: Responsible for conducting stability studies and documenting results for drugs with novel delivery systems as per US FDA guidelines.
Quality Assurance (QA) Team: Responsible for reviewing and approving stability study protocols and reports.
Regulatory Affairs Team: Responsible for ensuring that stability studies meet the
4) Procedure
4.1 Preparation for Stability Testing
4.1.1 Obtain and review the latest US FDA guidelines for stability testing of drugs with novel delivery systems.
4.1.2 Develop a stability protocol specific to the drug product, including study design, testing schedule, storage conditions, and testing parameters as
4.2 Selection of Batches and Samples
4.2.1 Select representative batches of the drug product, typically three primary batches manufactured using the proposed production process.
4.2.2 Prepare sufficient samples to cover the entire study duration, considering the number of time points and tests to be conducted.
4.3 Defining Storage Conditions and Time Points
4.3.1 Define the storage conditions according to FDA guidelines, typically including:
- Long-term stability: 25°C ± 2°C/60% RH ± 5% RH
- Accelerated stability: 40°C ± 2°C/75% RH ± 5% RH
4.3.2 Establish the time points for sampling, such as 0, 3, 6, 9, 12, 18, and 24 months for long-term studies, and additional time points for accelerated studies.
4.4 Conducting Stability Tests
4.4.1 Store samples under the defined conditions, ensuring proper handling to maintain the integrity of the novel delivery system.
4.4.2 At each specified time point, remove samples and conduct stability-indicating tests, including potency, purity, and performance testing relevant to the delivery system, as applicable.
4.4.3 Record all results meticulously in stability data sheets, ensuring accuracy and traceability of data.
5) Abbreviations, if any
FDA: United States Food and Drug Administration
QA: Quality Assurance
RH: Relative Humidity
6) Documents, if any
Stability protocol, stability data sheets, stability testing records, stability report, submission package to FDA.
7) Reference, if any
FDA Guidance for Industry: Stability Testing of Drugs with Novel Delivery Systems.
8) SOP Version
Version 1.0